Pfizer says Q2 2026 results beat expectations on non-COVID brand growth and cost discipline
PFE•Full-year guidance raised
Pfizer raised the midpoint of its full-year revenue guidance by USD 0.5 billion to USD 60.5 billion to USD 62.5 billion.
The company also cut its COVID revenue view to about USD 4 billion.
Q2 results topped expectations
Pfizer said its second-quarter 2026 results beat expectations, with revenue of USD 15 billion, up 1% operationally. Excluding COVID products, underlying revenue rose 5%.
Adjusted diluted EPS was USD 0.77, beating internal expectations. Management cited cost discipline and productivity gains despite higher Phase 3 activity.
Growth in launched and acquired products
Launched and acquired products generated USD 3.2 billion of revenue, up 18% operationally. Pfizer said growth was tempered by prior-year one-time items.
Performance was driven mainly by Eliquis, Padcev, the Vyndaqel family, and Lorbrena. The company also cited AI as supporting commercial execution and manufacturing yields.
Related News
Western Alliance Bancorporation announces BRL 1.44 per unit distribution, payable Sept. 2
Rein Therapeutics publishes first-in-human LTI-03 idiopathic pulmonary fibrosis data in Nature Communications
